microRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review)

Xiao,Yu-Feng; Yong,Xin; Fan,Ya-Han; Lü,Mu-Han; Yang,Shi-Ming; Hu,Chang-Jiang

doi:10.3892/or.2013.2525

microRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review)

Authors:
- Yu-Feng Xiao
- Xin Yong
- Ya-Han Fan
- Mu-Han Lü
- Shi-Ming Yang
- Chang-Jiang Hu
View Affiliations

Affiliations: Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China
Published online on: June 7, 2013 https://doi.org/10.3892/or.2013.2525
Pages: 535-544

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRNAs) are short non-coding RNA sequences that play important roles in the regulation of gene expression. They have significant regulatory functions in basic cellular processes, including differentiation, proliferation and apoptosis. miRNAs are differentially expressed in tumors, compared with normal tissues. Importantly, miRNAs are also stable and abundantly present in body fluids and feces. The high reproducibility, sensitivity and specificity of miRNAs in body fluids and feces enable miRNAs to be used as potential molecular markers for cancer screening. An increasingly large number of research studies have reported the role of miRNAs in this field. In the present review, we focused mainly on the application of detecting miRNAs in stool, sputum, pleural effusion and urine, to detect colon, lung and urological cancers, highlighting the role of miRNAs in early diagnosis and prognosis.

View Figures

View References

1	Corte H, Manceau G, Blons H and Laurent-Puig P: MicroRNA and colorectal cancer. Digest Liver Dis. 44:195–200. 2012. View Article : Google Scholar
2	Jemal A, Siegel R, Ward E, Hao YP, Xu JQ and Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
3	Frost JK, Ball WC Jr, Levin ML, et al: Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis. 130:549–554. 1984.PubMed/NCBI
4	Flehinger BJ, Kimmel M and Melamed MR: The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest. 101:1013–1018. 1992. View Article : Google Scholar : PubMed/NCBI
5	Patz EF Jr, Rossi S, Harpole DH Jr, Herndon JE and Goodman PC: Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest. 117:1568–1571. 2000. View Article : Google Scholar : PubMed/NCBI
6	Yu L, Todd NW, Xing LX, et al: Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 127:2870–2878. 2010. View Article : Google Scholar : PubMed/NCBI
7	Subramanian J and Simon R: Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 102:464–474. 2010. View Article : Google Scholar : PubMed/NCBI
8	Greer KB and Cooper GS: Receipt of colonoscopy is key to reduction of colorectal cancer mortality. Gastrointest Endosc. 76:365–366. 2012. View Article : Google Scholar : PubMed/NCBI
9	Chang KC and Yew WW: What is the role of autofluorescence bronchoscopy in screening lung cancer among silicotic subjects? reply. Int J Tuberc Lung Dis. 15:1277–1278. 2011. View Article : Google Scholar : PubMed/NCBI
10	Blick CG, Nazir SA, Mallett S, et al: Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int. 110:84–94. 2012. View Article : Google Scholar
11	Ladabaum U and Song K: Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology. 129:1151–1162. 2005. View Article : Google Scholar : PubMed/NCBI
12	Toloza EM, Harpole L and McCrory DC: Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 123:137S–146S. 2003. View Article : Google Scholar : PubMed/NCBI
13	van Rhijn BW, van der Poel HG and van der Kwast TH: Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 47:736–748. 2005.
14	Thunnissen FB: Sputum examination for early detection of lung cancer. J Clin Pathol. 56:805–810. 2003. View Article : Google Scholar : PubMed/NCBI
15	Simon MA, Lokeshwar VB and Soloway MS: Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol. 47:91–107. 2003. View Article : Google Scholar : PubMed/NCBI
16	Bassi P, De Marco V, De Lisa A, et al: Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int. 75:193–200. 2005. View Article : Google Scholar : PubMed/NCBI
17	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar
18	Shenouda SK and Alahari SK: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
19	Patnaik SK, Kannisto E, Mallick R and Yendamuri S: Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One. 6:e223792011.PubMed/NCBI
20	Kong YW, Ferland-McCollough D, Jackson TJ and Bushell M: microRNAs in cancer management. Lancet Oncol. 13:E249–E258. 2012. View Article : Google Scholar : PubMed/NCBI
21	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
22	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
23	Harfe BD: MicroRNAs in vertebrate development. Curr Opin Genet Dev. 15:410–415. 2005. View Article : Google Scholar
24	Kloosterman WP and Plasterk RHA: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
25	Mandke P, Wyatt N, Fraser J, Bates B, Berberich SJ and Markey MP: MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS One. 7:e420342012. View Article : Google Scholar : PubMed/NCBI
26	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
27	Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
28	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
29	Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
30	Ho AS, Huang X, Cao HB, et al: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 3:109–113. 2010. View Article : Google Scholar : PubMed/NCBI
31	Wu CW, Ng SSM, Dong YJ, et al: Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 61:739–745. 2012. View Article : Google Scholar : PubMed/NCBI
32	Xie Y, Todd NW, Liu ZQ, et al: Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 67:170–176. 2010. View Article : Google Scholar : PubMed/NCBI
33	Brase JC, Wuttig D, Kuner R and Sultmann H: Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 9:3062010. View Article : Google Scholar : PubMed/NCBI
34	Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G and Bonnerot C: Exosomal-like vesicles are present in human blood plasma. Int Immunol. 17:879–887. 2005. View Article : Google Scholar : PubMed/NCBI
35	van Niel G, Porto-Carreiro I, Simoes S and Raposo G: Exosomes: a common pathway for a specialized function. J Biochem. 140:13–21. 2006.PubMed/NCBI
36	Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ and Lotvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–672. 2007. View Article : Google Scholar : PubMed/NCBI
37	Hunter MP, Ismail N, Zhang X, et al: Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 3:e36942008. View Article : Google Scholar : PubMed/NCBI
38	Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD and Kloecker GH: Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 10:42–46. 2009. View Article : Google Scholar : PubMed/NCBI
39	Skog J, Wurdinger T, van Rijn S, et al: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 10:1470–1476. 2008. View Article : Google Scholar : PubMed/NCBI
40	Yu Z and Hecht NB: The DNA/RNA-binding protein, translin, binds microRNA122a and increases its in vivo stability. J Androl. 29:572–579. 2008. View Article : Google Scholar : PubMed/NCBI
41	Xie L, Chen X, Wang L, et al: Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer. 10:5912010. View Article : Google Scholar : PubMed/NCBI
42	Levine JS and Ahnen DJ: Clinical practice. Adenomatous polyps of the colon. N Engl J Med. 355:2551–2557. 2006. View Article : Google Scholar : PubMed/NCBI
43	Levin B, Lieberman DA, McFarland B, et al: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 134:1570–1595. 2008. View Article : Google Scholar
44	Lieberman DA and Weiss DG: One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 345:555–560. 2001. View Article : Google Scholar : PubMed/NCBI
45	Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA and Ross ME: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 351:2704–2714. 2004. View Article : Google Scholar : PubMed/NCBI
46	Hewitson P, Glasziou P, Irwig L, Towler B and Watson E: Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. CD0012162007. View Article : Google Scholar
47	Cotton PB, Durkalski VL, Benoit PC, et al: Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA. 291:1713–1719. 2004. View Article : Google Scholar : PubMed/NCBI
48	Mulhall BP, Veerappan GR and Jackson JL: Meta-analysis: computed tomographic colonography. Ann Intern Med. 142:635–650. 2005. View Article : Google Scholar : PubMed/NCBI
49	Johnson CD, Chen MH, Toledano AY, et al: Accuracy of CT colonography for detection of large adenomas and cancers. New Engl J Med. 359:1207–1217. 2008. View Article : Google Scholar : PubMed/NCBI
50	Coady-Fariborzian L, Angel LP and Procaccino JA: Perforated colon secondary to virtual colonoscopy: report of a case. Dis Colon Rectum. 47:1247–1249. 2004. View Article : Google Scholar : PubMed/NCBI
51	Kanaoka S, Yoshida K, Miura N, Sugimura H and Kajimura M: Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology. 127:422–427. 2004. View Article : Google Scholar : PubMed/NCBI
52	Ahlquist DA, Sargent DJ, Loprinzi CL, et al: Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 149:441–450. W4812008. View Article : Google Scholar : PubMed/NCBI
53	Brand RE, Ross ME and Shuber AP: Reproducibility of a multitarget stool-based DNA assay for colorectal cancer detection. Am J Gastroenterol. 99:1338–1341. 2004. View Article : Google Scholar : PubMed/NCBI
54	Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W and Amadori D: Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol. 1:377–383. 2003. View Article : Google Scholar : PubMed/NCBI
55	Yu YJ, Majumdar AP, Nechvatal JM, et al: Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev. 17:455–458. 2008.PubMed/NCBI
56	Zauber AG, Levin TR, Jaffe CC, Galen BA, Ransohoff DF and Brown ML: Implications of new colorectal cancer screening technologies for primary care practice. Med Care. 46:S138–S146. 2008. View Article : Google Scholar : PubMed/NCBI
57	Aslam MI, Taylor K, Pringle JH and Jameson JS: MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg. 96:702–710. 2009. View Article : Google Scholar : PubMed/NCBI
58	Ahmed FE, Jeffries CD, Vos PW, et al: Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics. 6:281–295. 2009.PubMed/NCBI
59	Link A, Balaguer F, Shen Y, et al: Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 19:1766–1774. 2010. View Article : Google Scholar : PubMed/NCBI
60	Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al: Differential expression of miR-144^* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 46:1391–1402. 2011.
61	Koga Y, Yasunaga M, Takahashi A, et al: MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res. 3:1435–1442. 2010. View Article : Google Scholar : PubMed/NCBI
62	Li JM, Zhao RH, Li ST, et al: Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer. Saudi Med J. 33:24–29. 2012.PubMed/NCBI
63	Kalimutho M, Di Cecilia S, Blanco GD, et al: Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer. 104:1770–1778. 2011. View Article : Google Scholar : PubMed/NCBI
64	Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001. View Article : Google Scholar
65	Xing LX, Todd NW, Yu L, Fang HB and Jiang F: Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Modern Pathol. 23:1157–1164. 2010. View Article : Google Scholar : PubMed/NCBI
66	Akira M: High-resolution CT in the evaluation of occupational and environmental disease. Radiol Clin North Am. 40:43–59. 2002. View Article : Google Scholar : PubMed/NCBI
67	Bastarrika G, Garcia-Velloso MJ, Lozano MD, et al: Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med. 171:1378–1383. 2005. View Article : Google Scholar : PubMed/NCBI
68	Gohagan JK, Marcus PM, Fagerstrom RM, et al: Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer. 47:9–15. 2005. View Article : Google Scholar : PubMed/NCBI
69	Swensen SJ, Jett JR, Hartman TE, et al: Lung cancer screening with CT: Mayo Clinic experience. Radiology. 226:756–761. 2003. View Article : Google Scholar : PubMed/NCBI
70	Koga H, Eguchi K, Shinkai T, et al: Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients. Jpn J Clin Oncol. 24:263–268. 1994.PubMed/NCBI
71	Sun S, Schiller JH and Gazdar AF: Lung cancer in never smokers: a different disease. Nat Rev Cancer. 7:778–790. 2007. View Article : Google Scholar : PubMed/NCBI
72	Hirsch FR, Franklin WA, Gazdar AF and Bunn PA Jr: Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res. 7:5–22. 2001.PubMed/NCBI
73	Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL and Massion PP: The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res. 5:992–1006. 2012. View Article : Google Scholar : PubMed/NCBI
74	Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 4:707–717. 2004. View Article : Google Scholar : PubMed/NCBI
75	Castro M, Grau L, Puerta P, et al: Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med. 8:862010. View Article : Google Scholar : PubMed/NCBI
76	Halling KC, Rickman OB, Kipp BR, Harwood AR, Doerr CH and Jett JR: A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest. 130:694–701. 2006. View Article : Google Scholar : PubMed/NCBI
77	Beane J, Sebastiani P, Whitfield TH, et al: A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res. 1:56–64. 2008. View Article : Google Scholar : PubMed/NCBI
78	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
79	Greenberg AK, Rimal B, Felner K, et al: S-adenosylmethionine as a biomarker for the early detection of lung cancer. Chest. 132:1247–1252. 2007. View Article : Google Scholar : PubMed/NCBI
80	Showe MK, Vachani A, Kossenkov AV, et al: Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res. 69:9202–9210. 2009. View Article : Google Scholar
81	Lai CY, Yu SL, Hsieh MH, et al: MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One. 6:e216352011. View Article : Google Scholar : PubMed/NCBI
82	Peck K, Sher YP, Shih JY, Roffler SR, Wu CW and Yang PC: Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res. 58:2761–2765. 1998.PubMed/NCBI
83	van der Drift MA, Prinsen CFM, Hol BEA, et al: Can free DNA be detected in sputum of lung cancer patients? Lung Cancer. 61:385–390. 2008.PubMed/NCBI
84	Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
85	Neragi-Miandoab S: Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer. 54:1–9. 2006. View Article : Google Scholar : PubMed/NCBI
86	Wang T, Lv M, Shen S, et al: Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS One. 7:e432682012. View Article : Google Scholar : PubMed/NCBI
87	Lee JH, Hong YS, Ryu JS and Chang JH: p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion. Lung Cancer. 44:33–42. 2004. View Article : Google Scholar : PubMed/NCBI
88	Spector M and Pollak JS: Management of malignant pleural effusions. Semin Respir Crit Care Med. 29:405–413. 2008. View Article : Google Scholar : PubMed/NCBI
89	Topolcan O, Holubec L, Polivkova V, et al: Tumor markers in pleural effusions. Anticancer Res. 27:1921–1924. 2007.PubMed/NCBI
90	Katayama H, Hiraki A, Aoe K, et al: Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer. 120:2191–2195. 2007. View Article : Google Scholar : PubMed/NCBI
91	Wang T, Qian X, Wang Z, et al: Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int J Cancer. 125:1921–1925. 2009. View Article : Google Scholar : PubMed/NCBI
92	Nair VS, Maeda LS and Ioannidis JPA: Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst. 104:528–540. 2012. View Article : Google Scholar : PubMed/NCBI
93	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
94	Snowdon J, Boag S, Feilotter H, Izard J and Siemens DR: A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J. 7:28–32. 2013. View Article : Google Scholar : PubMed/NCBI
95	Yamada Y, Enokida H, Kojima S, et al: MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 102:522–529. 2011. View Article : Google Scholar : PubMed/NCBI
96	Ratliff TL: Urine markers for bladder cancer surveillance: a systematic review. J Urol. 174:2065–2066. 2005. View Article : Google Scholar : PubMed/NCBI
97	Sarosdy MF, Hudson MA, Ellis WJ, et al: Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology. 50:349–353. 1997. View Article : Google Scholar : PubMed/NCBI
98	Carpinito GA, Stadler WM, Briggman JV, et al: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 156:1280–1285. 1996. View Article : Google Scholar : PubMed/NCBI
99	Fradet Y and Lockhard C: Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt™. Can J Urol. 4:400–405. 1997.PubMed/NCBI
100	Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin. 50:7–33. 2000. View Article : Google Scholar
101	Wang G, Chan ESY, Kwan BCH, et al: Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer. 10:106–113. 2012. View Article : Google Scholar : PubMed/NCBI
102	Roos PH and Jakubowski N: Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids. Bioanalysis. 2:295–309. 2010. View Article : Google Scholar : PubMed/NCBI
103	Puerta-Gil P, Garcia-Baquero R, Jia AY, et al: miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 180:1808–1815. 2012. View Article : Google Scholar : PubMed/NCBI
104	Hanke M, Hoefig K, Merz H, et al: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 28:655–661. 2010. View Article : Google Scholar : PubMed/NCBI
105	Veerla S, Lindgren D, Kvist A, et al: MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer. 124:2236–2242. 2009. View Article : Google Scholar : PubMed/NCBI
106	Han Y, Chen J, Zhao X, et al: MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One. 6:e182862011. View Article : Google Scholar : PubMed/NCBI
107	Noguchi S, Mori T, Hoshino Y, et al: MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 307:211–220. 2011. View Article : Google Scholar : PubMed/NCBI
108	Kassouf W, Black PC, Tuziak T, et al: Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 179:353–358. 2008. View Article : Google Scholar : PubMed/NCBI
109	Junttila TT, Laato M, Vahlberg T, et al: Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res. 9:5346–5357. 2003.
110	Cissell KA and Deo SK: Trends in microRNA detection. Anal Bioanal Chem. 394:1109–1116. 2009. View Article : Google Scholar : PubMed/NCBI
111	de Planell-Saguer M and Rodicio MC: Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta. 699:134–152. 2011.PubMed/NCBI
112	Ach RA, Wang H and Curry B: Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechnol. 8:692008. View Article : Google Scholar : PubMed/NCBI
113	de Planell-Saguer M and Rodicio MC: Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta. 699:134–152. 2011.PubMed/NCBI
114	Sarver AL: Toward understanding the informatics and statistical aspects of micro-RNA profiling. J Cardiovasc Transl Res. 3:204–211. 2010. View Article : Google Scholar : PubMed/NCBI
115	Valoczi A, Hornyik C, Varga N, Burgyan J, Kauppinen S and Havelda Z: Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res. 32:e1752004. View Article : Google Scholar : PubMed/NCBI
116	Pall GS, Codony-Servat C, Byrne J, Ritchie L and Hamilton A: Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot. Nucleic Acids Res. 35:e602007. View Article : Google Scholar : PubMed/NCBI
117	Varallyay E, Burgyan J and Havelda Z: MicroRNA detection by northern blotting using locked nucleic acid probes. Nat Protoc. 3:190–196. 2008. View Article : Google Scholar : PubMed/NCBI
118	Chamnongpol S, Maroney PA and Nilsen TW: A rapid, quantitative assay for direct detection of microRNAs and other small RNAs using splinted ligation. Methods Mol Biol. 667:3–17. 2010. View Article : Google Scholar : PubMed/NCBI
119	Cissell KA, Rahimi Y, Shrestha S, Hunt EA and Deo SK: Bioluminescence-based detection of microRNA, miR21 in breast cancer cells. Anal Chem. 80:2319–2325. 2008. View Article : Google Scholar : PubMed/NCBI
120	Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
121	Weaver S, Dube S, Mir A, et al: Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution. Methods. 50:271–276. 2010. View Article : Google Scholar : PubMed/NCBI
122	Raymond CK, Roberts BS, Garrett-Engele P, Lim LP and Johnson JM: Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. RNA. 11:1737–1744. 2005. View Article : Google Scholar : PubMed/NCBI
123	Neely LA, Patel S, Garver J, et al: A single-molecule method for the quantitation of microRNA gene expression. Nat Methods. 3:41–46. 2006. View Article : Google Scholar : PubMed/NCBI
124	Kloosterman WP, Wienholds E, de Bruijn E, Kauppinen S and Plasterk RHA: In situ detection of miRNAs in animal embryos using LNA-modified oligonucteotide probes. Nat Methods. 3:27–29. 2006. View Article : Google Scholar : PubMed/NCBI
125	de Planell-Saguer M, Rodicio MC and Mourelatos Z: Rapid in situ codetection of noncoding RNAs and proteins in cells and formalin-fixed paraffin-embedded tissue sections without protease treatment. Nat Protoc. 5:1061–1073. 2010.PubMed/NCBI
126	Obernosterer G, Martinez J and Alenius M: Locked nucleic acid-based in situ detection of microRNAs in mouse tissue sections. Nat Protoc. 2:1508–1514. 2007. View Article : Google Scholar : PubMed/NCBI
127	Nelson PT, Baldwin DA, Kloosterman WP, Kauppinen S, Plasterk RHA and Mourelatos Z: RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA. 12:187–191. 2006. View Article : Google Scholar : PubMed/NCBI
128	Liu CG, Calin GA, Volinia S and Croce CM: MicroRNA expression profiling using microarrays. Nat Protoc. 3:563–578. 2008. View Article : Google Scholar : PubMed/NCBI
129	Li W and Ruan KC: MicroRNA detection by microarray. Anal Bioanal Chem. 394:1117–1124. 2009. View Article : Google Scholar : PubMed/NCBI
130	Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW and Mourelatos Z: Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods. 1:155–161. 2004. View Article : Google Scholar : PubMed/NCBI
131	Takada S and Mano H: Profiling of microRNA expression by mRAP. Nat Protoc. 2:3136–3145. 2007. View Article : Google Scholar : PubMed/NCBI
132	Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
133	Weber JA, Baxter DH, Zhang SL, et al: The microRNA spectrum in 12 body fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI
134	Kanaan Z, Rai SN, Eichenberger MR, et al: Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 256:544–551. 2012. View Article : Google Scholar : PubMed/NCBI
135	Li BS, Zhao YL, Guo G, et al: Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 7:e416292012. View Article : Google Scholar : PubMed/NCBI
136	Zhang X, Cui L, Ye G, et al: Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol. 33:2349–2355. 2012. View Article : Google Scholar : PubMed/NCBI
137	Janakiram NB and Rao CV: Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin. 29:1–20. 2008. View Article : Google Scholar : PubMed/NCBI
138	Dong Y, Wu WK, Wu CW, Sung JJ, Yu J and Ng SS: MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br J Cancer. 104:893–898. 2011. View Article : Google Scholar : PubMed/NCBI